Accéder au contenu
Merck
Toutes les photos(1)

Documents

V-004

Supelco

Venlafaxine hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C17H28ClNO2
Numéro CAS:
Poids moléculaire :
313.86
Numéro CE :
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Forme

liquid

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in methanol (as free base)

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

Cl.COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2

InChI

1S/C17H27NO2.ClH/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14;/h7-10,16,19H,4-6,11-13H2,1-3H3;1H

Clé InChI

QYRYFNHXARDNFZ-UHFFFAOYSA-N

Informations sur le gène

Description générale

A Certified Snap-N-Spike® Solution suitable for many LC/MS and GC/MS applications from forensic or clinical toxicology analysis to urine drug testing. Also known by the brand name Effexor®, venlafaxine is an SNRI antidepressant approved for the treatment of major depressive and general anxiety disorders.

Application


  • Reliable Dissolved Oxygen Detection: Reliable detection of dissolved oxygen is vital in enzymatic studies and biochemical reactions where oxygen plays a regulatory or reactive role, impacting the kinetics and outcomes of these reactions (Kusanto et al., 2021).


Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Effexor is a registered trademark of American Home Product Corp.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogrammes

FlameSkull and crossbonesHealth hazard

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Aaron S Heller et al.
The American journal of psychiatry, 170(2), 197-206 (2012-12-12)
OBJECTIVE Deficits in positive affect and their neural bases have been associated with major depression. However, whether reductions in positive affect result solely from an overall reduction in nucleus accumbens activity and fronto-striatal connectivity or the additional inability to sustain
Venlafaxine: preeclampsia and eclampsia.
Prescrire international, 21(131), 240-240 (2012-11-30)
S Fenli et al.
European review for medical and pharmacological sciences, 17(1), 41-48 (2013-01-19)
Venlafaxine is a new antidepressant that has a chemical structure and neuropharmacologic profile distinct from those of existing antidepressants. The studies about the mechanism of pharmacological action of venlafaxine mostly investigated the effects of venlafaxine on 5-hydroxytryptamine (5-HT), norepinephrine (NE)
Danuta Szkutnik-Fiedler et al.
Pharmacological reports : PR, 64(6), 1350-1358 (2013-02-15)
The aim of this study was to evaluate antidepressant-like effect (Porsolt test), locomotor activity and motor coordination of joint administration of tramadol (TRM) and venlafaxine (VEN) in rats. The tests were performed on male Wistar rats after single and chronic
Depersonalization and derealization syndrome: report on a case study and pharmacological management.
Ana Salgado et al.
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 34(4), 505-508 (2013-02-23)

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique